For research use only. Not for therapeutic Use.
<p style=/line-height:25px/>Etifoxine(HOE 36-801) is potentiator of GABAA receptor function in cultured neurons. Etifoxine preferentially acts on β2 or β3 subunit-containing GABAA receptors.<br>IC50 value:<br>Target: GABAA receptor<br>Etifoxine exhibits anxiolytic activity in rodents and humans with no sedative, myorelaxant or mnesic side effects. Etifoxine acts as a ligand of the translocator protein (TSPO); promotes axonal regeneration.</p>
Catalog Number | I002661 |
CAS Number | 21715-46-8 |
Synonyms | 6-chloro-N-ethyl-4-methyl-4-phenyl-3,1-benzoxazin-2-amine |
Molecular Formula | C17H17ClN2O |
Purity | ≥95% |
Target | GABA Receptor |
Solubility | 10 mM in DMSO |
Storage | Store at -20°C |
InChIKey | IBYCYJFUEJQSMK-UHFFFAOYSA-N |
Reference | <p style=/line-height:25px/> <br>[2]. Bourin M, Hascot M. Implication of 5-HT2 receptor subtypes in the mechanism of action of the GABAergic compound etifoxine in the four-plate test in Swiss mice. Behav Brain Res. 2010 Apr 2;208(2):352-8. <br>[3]. Gee KW, Tran MB, Hogenkamp DJ, et al. Limiting activity at beta1-subunit-containing GABAA receptor subtypes reduces ataxia. J Pharmacol Exp Ther. 2010 Mar;332(3):1040-53. <br>[4]. Aouad M, Charlet A, Rodeau JL, et al. Reduction and prevention of vincristine-induced neuropathic pain symptoms by the non-benzodiazepine anxiolytic etifoxine are mediated by 3alpha-reduced neurosteroids. Pain. 2009 Dec 15;147(1-3):54-9. <br>[5]. Girard C, Liu S, Cadepond F, et al. Etifoxine improves peripheral nerve regeneration and functional recovery. Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20505-10. </p> |